The Nuts and Bolts of SARS-CoV-2 Spike Receptor-Binding Domain Heterologous Expression.


Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
02 12 2021
Historique:
received: 28 10 2021
revised: 27 11 2021
accepted: 30 11 2021
entrez: 24 12 2021
pubmed: 25 12 2021
medline: 6 1 2022
Statut: epublish

Résumé

COVID-19 is a highly infectious disease caused by a newly emerged coronavirus (SARS-CoV-2) that has rapidly progressed into a pandemic. This unprecedent emergency has stressed the significance of developing effective therapeutics to fight the current and future outbreaks. The receptor-binding domain (RBD) of the SARS-CoV-2 surface Spike protein is the main target for vaccines and represents a helpful "tool" to produce neutralizing antibodies or diagnostic kits. In this work, we provide a detailed characterization of the native RBD produced in three major model systems:

Identifiants

pubmed: 34944456
pii: biom11121812
doi: 10.3390/biom11121812
pmc: PMC8699011
pii:
doi:

Substances chimiques

Recombinant Proteins 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Regione Lazio - Lazio Innova
ID : POR FESR 2014-2020, Avviso Pubblico "EMERGENZA CORONAVIRUS E OLTRE", CUP F84E21000030006

Références

J Gen Virol. 2006 Jun;87(Pt 6):1691-1695
pubmed: 16690935
Protein Sci. 1995 Oct;4(10):2138-48
pubmed: 8535251
Int J Antimicrob Agents. 2020 Mar;55(3):105924
pubmed: 32081636
Viruses. 2021 Mar 09;13(3):
pubmed: 33803400
World J Gastroenterol. 2005 Oct 21;11(39):6159-64
pubmed: 16273643
Mol Ther. 2021 Jun 2;29(6):1984-2000
pubmed: 33578036
Front Cell Infect Microbiol. 2020 Nov 25;10:587269
pubmed: 33324574
Int J Biol Macromol. 2021 Apr 30;177:1-9
pubmed: 33577820
Science. 2020 Jul 17;369(6501):330-333
pubmed: 32366695
Biophys J. 2021 Mar 16;120(6):1011-1019
pubmed: 33607086
Nucleic Acids Res. 2018 Jul 2;46(W1):W315-W322
pubmed: 29893907
Mol Ther. 2022 Jan 5;30(1):311-326
pubmed: 34547465
Emerg Microbes Infect. 2020 Dec;9(1):2076-2090
pubmed: 32897177
Gene Rep. 2021 Jun;23:101140
pubmed: 33869895
Sci Rep. 2020 Dec 11;10(1):21779
pubmed: 33311634
Proc Natl Acad Sci U S A. 2015 Jun 16;112(24):E3095-103
pubmed: 26038575
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
J Biol Chem. 2021 Oct;297(4):101208
pubmed: 34543625
Nature. 2021 Mar;591(7849):293-299
pubmed: 33494095
Sci Rep. 2021 Jan 13;11(1):947
pubmed: 33441822
Comput Struct Biotechnol J. 2021;19:2508-2517
pubmed: 33936564
J Gen Virol. 2020 Sep;101(9):925-940
pubmed: 32568027
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
Thromb Haemost. 2020 Dec;120(12):1700-1715
pubmed: 33368089
Cell Mol Immunol. 2020 Jun;17(6):613-620
pubmed: 32203189
J Immunol Methods. 2021 Aug;495:113082
pubmed: 34051226
J Transl Med. 2020 Jun 3;18(1):222
pubmed: 32493510
Protein Sci. 2006 Mar;15(3):635-9
pubmed: 16452626
JAMA. 2021 Apr 6;325(13):1318-1320
pubmed: 33635317
Glycobiology. 2020 Dec 9;30(12):981-988
pubmed: 32363391
Brief Bioinform. 2021 Mar 22;22(2):1239-1253
pubmed: 33006605
ACS Cent Sci. 2020 Oct 28;6(10):1722-1734
pubmed: 33140034
Front Plant Sci. 2021 Jun 15;12:689104
pubmed: 34211491
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Signal Transduct Target Ther. 2021 Feb 26;6(1):95
pubmed: 33637679

Auteurs

Mariano Maffei (M)

Evvivax Biotech, Via di Castel Romano 100, 00128 Rome, Italy.

Linda Celeste Montemiglio (LC)

Institute of Molecular Biology and Pathology (IBPM), National Research Council, c/o Department of Biochemical Sciences "Alessandro Rossi Fanelli", Sapienza, University of Rome, P. le Aldo Moro, 5, 00185 Rome, Italy.

Grazia Vitagliano (G)

Takis Biotech, Via di Castel Romano 100, 00128 Rome, Italy.

Luigi Fedele (L)

Takis Biotech, Via di Castel Romano 100, 00128 Rome, Italy.

Shaila Sellathurai (S)

Takis Biotech, Via di Castel Romano 100, 00128 Rome, Italy.

Federica Bucci (F)

Takis Biotech, Via di Castel Romano 100, 00128 Rome, Italy.

Mirco Compagnone (M)

Neomatrix Biotech, Via di Castel Romano 100, 00128 Rome, Italy.

Valerio Chiarini (V)

Takis Biotech, Via di Castel Romano 100, 00128 Rome, Italy.

Cécile Exertier (C)

Department of Biochemical Sciences "Alessandro Rossi Fanelli", Sapienza, University of Rome, P. le Aldo Moro, 5, 00185 Rome, Italy.

Alessia Muzi (A)

Takis Biotech, Via di Castel Romano 100, 00128 Rome, Italy.

Giuseppe Roscilli (G)

Evvivax Biotech, Via di Castel Romano 100, 00128 Rome, Italy.
Takis Biotech, Via di Castel Romano 100, 00128 Rome, Italy.

Beatrice Vallone (B)

Department of Biochemical Sciences "Alessandro Rossi Fanelli", Sapienza, University of Rome, P. le Aldo Moro, 5, 00185 Rome, Italy.

Emanuele Marra (E)

Evvivax Biotech, Via di Castel Romano 100, 00128 Rome, Italy.
Takis Biotech, Via di Castel Romano 100, 00128 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH